Latest News

BrightFocus-funded Dr. Maya Koronyo-Hamaoui is the senior author on a groundbreaking publication that reported the ACE protein, which can increase blood pressure to dangerous levels in the body’s blood stream, can actually help to clear beta-amyloid in the brain by stimulating the immune system.

Experts have long recognized that the number of deaths from Alzheimer’s disease (AD) tends to be underreported. Now a new study published in Neurology attempts to quantify that under-reporting and projects the AD mortality rate to be five to six times higher than official estimates, suggesting that AD may be responsible for more than 500,000 annual deaths in the United States.

A group of researchers based at the University of California, San Francisco (UCSF), have shown that when cardiovascular risk factors (CVRF) such as elevated glucose and high blood pressure begin in early adulthood, they are associated with significantly worse cognitive function in middle age compared with having no CVRF.

University of California, Irvine (UCI) researchers, led by BrightFocus researcher Frank M. LaFerla, PhD, have published positive findings from mice studies that suggest cell therapy slows down brain changes and symptoms linked to Alzheimer’s disease.

Download the fall 2013 issue of our glaucoma newsletter to learn about an FDA-approved glaucoma drug called Simbrinza™ Suspension, strategies for everyday life with glaucoma, and much more.

Download the winter 2014 issue of our glaucoma newsletter to learn about a recently discovered common genetic marker for elevated intraocular pressure, risks associated with certain glaucoma drugs, and much more.

Download the summer 2014 issue of our glaucoma newsletter to learn about a set of molecules that could block myocilin accumulation, drug-delivering contact lenses for glaucoma patients, and much more.